rationale for verify: rusfertide added to ongoing therapy in patients with polycythemia vera
Published 1 year ago • 136 plays • Length 1:56Download video MP4
Download video MP3
Similar videos
-
1:30
the verify trial: rusfertide in patients with polycythemia vera
-
2:08
phase iii trial of rusfertide in patients with polycythemia vera
-
7:26
rusfertide: a promising option to control hematocrit levels in patients with polycythemia vera
-
3:23
the role of rusfertide in polycythemia vera
-
5:42
an update on revive: rusfertide in patients with polycythemia vera
-
9:07
revive: targeted therapy for uncontrolled erythrocytosis in pv with rusfertide
-
1:55
an update on the safety and efficacy of rusfertide in polycythemia vera
-
1:12
contemporary challenges in polycythemia vera management
-
10:20
new guidelines for the treatment and management of polycythemia vera
-
3:07
the current treatment algorithm for polycythemia vera
-
5:00
long-term results of the phase ii revive study evaluating rusfertide in patients with pv
-
3:02
current and emerging management strategies in polycythemia vera
-
3:10
promising trials in polycythemia vera
-
5:56
rusfertide reduces need for therapeutic phlebotomy in pv patients
-
2:46
an update on emerging therapies for the treatment of polycythemia vera
-
1:39
upcoming agents in et and pv
-
1:52
cytoreductive therapy for patients with pv
-
1:21
response-adapted therapy with copanlisib and rituximab for previously untreated fl
-
0:54
study design for persist-2 and other upcoming trials of pacritinib